Why Novartis Split: Capital Allocation and the Shrinking Multiple
Novartis shareholders started 2024 with an unfamiliar ticker blinking at them. The Sandoz spin-out, delivered as an all-share distribution and valued at roughly $10.5 billion, landed at a moment when generic drug makers are hardly the market darlings they once were. It’s a far cry from 2014, when Novartis built up Sandoz through $16 billion in asset swaps, betting that scale and integration would be the name of the game. Sandoz delivered, sort of. By 2022, revenue was steady but stubbornly flat at about $9.6 billion, margins were parked under 20 percent, and the market split: Novartis’s branded medicines traded at forward multiples in the mid-teens; Sandoz hovered closer to 6x EBITDA. The argument for a split became impossible to ignore.
Shedding Sandoz freed Novartis to chase higher-return assets and, just as important for a public company, to reclaim its multiple. For Sandoz, the spinoff means full independence right when the generics model is under the harshest pressure it’s faced in decades, especially in the US, where aggressive PBMs and relentless price compression are simply facts of life. The company’s big hope now rests on biosimilars: less commoditized, potentially higher-margin, and a possible buffer against the old generic pill grind. But let’s be honest, Sandoz is up against heavyweights like Amgen, Pfizer, Biocon, and Korean giants in biosimilars, while still having to protect a core generics business that faces unyielding margin squeeze from tough buyers with plenty of options.
Scale vs. Margin in Biosimilars: Can Sandoz Win?
Sandoz’s 2023 biosimilar revenue landed just under $2.5 billion, over 60 percent of it from Europe. The US market? Still frustratingly elusive. There’s talk about a post-Humira biosimilar surge, but so far, pricing and uptake aren’t matching the optimism. The margin promise of biosimilars, more predictable, less cutthroat than small-molecule generics, has come through in fits and starts. The single biggest variable: can Sandoz shift its US biosimilar share from today’s modest mid-single digits to something approaching 20 percent of sales by 2026? That's the ballgame.
Cracking that code requires more than launching molecules. Success hinges on convincing payers and plan sponsors to embrace biosimilars on formularies, and those decisions are driven as much by PBMs as by slick commercial strategies. If Sandoz can lead on launches like adalimumab, ranibizumab, or pegfilgrastim, biosimilar gross margins might climb into the mid-30s, a real jump from the low 20s seen in generics. But competition has never been fiercer. Amgen, Viatris, Boehringer Ingelheim, they all have their sites set on Humira and Neulasta biosimilar shares. Recent RxInfo.ai data tells a blunt story: net biosimilar discounts regularly reach 50 percent off brand prices within a year of launch, slicing straight through those projected margin gains.
Gaining share isn’t the whole picture. Sandoz’s ability to fund next-gen biosimilars, aflibercept, ustekinumab, Eylea, depends entirely on cash flow from what it’s selling today. Accelerating price erosion, particularly stateside, could force Sandoz into tough calls: double down on a few launches, let others drop. There’s a real dilemma here: fight for share with vanishing prices, or conserve R&D for launches that might actually move the needle? No easy answer, and the market won’t hand out patience for free.
Generics After the Spin: Pressure Without a Safety Net
Conventional generics pay most of Sandoz’s bills. We’re talking standard pills and injectables whose prices have been sliding for a decade as buyers, PBMs, group purchasing organizations, health systems, tighten the screws ever harder. With the Novartis umbrella gone, Sandoz faces the negotiating table with less capital and zero big-pharma backup. US generics sales? Down from more than $2.5 billion in 2018 to under $2 billion last year. The RxPBM.ai platform shows unit prices for top molecules dropping 15-20 percent in just three years. The squeeze keeps tightening.
Leadership knows the score. The North America unit now emphasizes margin over volume, walking away from contracts that don’t pay. Sure, that’s rational, no point in holding the “low-cost producer” prize if the prize is underwater. But the tradeoff is lost share in some key areas. And now Sandoz has the unenviable job of convincing Wall Street it can grow earnings in a world where flat volumes and mid-single-digit price declines count as a win. More portfolio pruning and exiting of commoditized segments are inevitable. Expect Sandoz to steer toward tough, complex generics and specialty injectables. The scattershot ANDA era is gone, and honestly, it’s about time.
That shift lands on buyers, too. For specialty pharmacies, health systems, and even hospital purchasing teams, the story going forward is less about list prices and more about access and availability. Sandoz, and its peers, are getting choosier, which means some drugs will see patchier supply and those deep, old-school discounts may evaporate. Pricing power has moved to the buyers. Sandoz, now out on its own, has no margin for error. There’s not much nostalgia for the safety net, but there’s no replacing it either.
How Will Buyers and Competitors Respond? 2025-2026 Preview
Next year, Sandoz faces its proving ground when the next round of biosimilars hit the US market. Investors will look past revenue headlines and go straight to margins, can the company actually sustain biosimilar gross margins above 30 percent, given the post-launch discount feeding frenzy? Large employers and plan sponsors will be watching, hoping for lower net costs on biologics through the RxBenefits.ai platform. But formulary adoption in the US still lags, trailing Europe by a frustrating margin.
Meanwhile, the competition isn’t waiting. Biocon and Samsung Bioepis are investing aggressively stateside; Amgen, with its own specialty pharmacy muscle, isn’t giving any ground. Sandoz will need more than scale, it needs agility, smarter contracting, and credible education to avoid getting swept aside. Its new capital structure, let’s be honest, limits how bold it can be. The biosimilar market won’t see another “race to the bottom,” but investor margin dreams from two years ago look awfully optimistic today.
All this turns Sandoz into a litmus test for the post-spin world. Can it hold “reliable supplier” status, outflanking Big Pharma without getting undercut by highly-levered Asian competitors? Hospitals and PBMs are ready to pit biosimilar vendors against each other, hunting for deeper discounts and sweeter contract terms. RxInfo.ai pricing data already suggest net prices for major biosimilar classes could slip another 10-15 percent by late 2025, especially as more producers jump into crowded markets like adalimumab and trastuzumab. Feels like everyone’s lining up for a piece.
So where does that leave the industry? The Sandoz spin has become a marker: generics are now about surviving, biosimilars about scaling, and winners must do both while holding onto margins. Sandoz still has the reach and the molecules to make a case, at least for now. Whether that converts into sustained growth or just prolongs another bruising round of price wars, that’s up in the air. The market’s open, and the clock’s running.
